{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:54:39Z","timestamp":1789167279231,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-155, 2022-PUMCH-B-016"],"award-info":[{"award-number":["2022-PUMCH-A-155, 2022-PUMCH-B-016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the incidence of malignancies in acromegaly and to identify risk factors for newly-diagnostic cancers, especially the excessive growth hormone (GH) and insulin-like growth factor-1 (IGF-1).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort including 1738 consecutive hospitalized patients with acromegaly in a single referral center between 2012 and 2020 (mean follow-up 4.3 years). A gender- and age-matched case-control study (280 patients from the cohort) was performed for risk factor analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred thirteen malignancies (67 diagnosed after acromegaly) were observed. The overall newly-diagnostic cancer risk of acromegaly was higher than the general population (standardized incidence ratio (SIR) 2.81; 95% CI 2.18\u20133.57). The risk of thyroid cancer (<jats:italic>n<\/jats:italic>\u2009=\u200933, SIR 21.42; 95% CI 13.74\u201330.08) and colorectal cancer (<jats:italic>n<\/jats:italic>\u2009=\u20098, SIR 3.17; 95% CI 1.37\u20136.25) was elevated. In the overall cohort, IGF-1 (ULN: 1.27 vs. 0.94, <jats:italic>p<\/jats:italic>\u2009=\u20090.057), GH (1.30 vs. 1.00\u2009ng\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.12), and disease-controlled rate (34.9% vs. 45.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.203) at the last visit did not reach significance between patients with and without post-diagnostic cancer. In the case-control study, GH (1.80 vs. 0.90\u2009ng\/ml, <jats:italic>p<\/jats:italic>\u2009=\u20090.018) and IGF-1 (ULN: 1.27 vs. 0.91, <jats:italic>p<\/jats:italic>\u2009=\u20090.003) at the last visit were higher in patients with post-diagnostic cancers, with a lower disease-controlled rate. Elder age was a risk factor for cancer. Other metabolic comorbidities and the size of pituitary tumors were similar.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The risk of malignancies, especially thyroid cancer, was increased in patients with acromegaly in our center. More cancer screening should be considered when managing acromegaly, especially in patients with higher posttreatment GH and IGF-1.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-023-03447-y","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T19:01:38Z","timestamp":1689274898000},"page":"368-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study"],"prefix":"10.1007","volume":"82","author":[{"given":"Tongxin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengying","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-474X","authenticated-orcid":false,"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5172-6870","authenticated-orcid":false,"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"issue":"11","key":"3447_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/JCI39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest 119(11), 3189\u20133202 (2009). https:\/\/doi.org\/10.1172\/JCI39375","journal-title":"J. Clin. Invest"},{"issue":"1","key":"3447_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40(1), 268\u2013332 (2019). https:\/\/doi.org\/10.1210\/er.2018-00115","journal-title":"Endocr. Rev."},{"issue":"12","key":"3447_CR3","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"M. Mercado, B. Gonzalez, G. Vargas, C. Ramirez, A.L.E. de los Monteros, E. Sosa et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. 99(12), 4438\u20134446 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2670","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"3447_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/EJE-16-1064","volume":"176","author":"L Maione","year":"2017","unstructured":"L. Maione, T. Brue, A. Beckers, B. Delemer, P. Petrossians, F. Borson-Chazot et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur. J. Endocrinol. 176(5), 645\u2013655 (2017). https:\/\/doi.org\/10.1530\/EJE-16-1064","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"3447_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1530\/EJE-18-0015","volume":"178","author":"D Esposito","year":"2018","unstructured":"D. Esposito, O. Ragnarsson, D. Granfeldt, T. Marlow, G. Johannsson, D.S. Olsson, Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur. J. Endocrinol. 178(5), 459\u2013469 (2018). https:\/\/doi.org\/10.1530\/EJE-18-0015","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"3447_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1530\/ERC-16-0106","volume":"23","author":"E Ritvonen","year":"2016","unstructured":"E. Ritvonen, E. L\u00f6yttyniemi, P. Jaatinen, T. Ebeling, L. Moilanen, P. Nuutila et al. Mortality in acromegaly: a 20-year follow-up study. Endocr. Relat. Cancer 23(6), 469\u2013480 (2016). https:\/\/doi.org\/10.1530\/ERC-16-0106","journal-title":"Endocr. Relat. Cancer"},{"issue":"6","key":"3447_CR7","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1210\/jc.2017-02457","volume":"103","author":"J Dal","year":"2018","unstructured":"J. Dal, M.Z. Leisner, K. Hermansen, D.K. Farkas, M. Bengtsen, C. Kistorp et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J. Clin. Endocrinol. Metab. 103(6), 2182\u20132188 (2018). https:\/\/doi.org\/10.1210\/jc.2017-02457","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"3447_CR8","doi-asserted-by":"publisher","first-page":"D1","DOI":"10.1530\/EJE-19-1009","volume":"183","author":"M Terzolo","year":"2020","unstructured":"M. Terzolo, S. Puglisi, G. Reimondo, C. Dimopoulou, G.K. Stalla, Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population. Eur. J. Endocrinol. 183(4), D1\u2013D13 (2020). https:\/\/doi.org\/10.1530\/EJE-19-1009","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"3447_CR9","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/EJE-16-0178","volume":"175","author":"CL Boguszewski","year":"2016","unstructured":"C.L. Boguszewski, J. Ayuk, MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited. Eur. J. Endocrinol. 175(4), R147\u2013R156 (2016). https:\/\/doi.org\/10.1530\/EJE-16-0178","journal-title":"Eur. J. Endocrinol."},{"key":"3447_CR10","doi-asserted-by":"publisher","unstructured":"M. Fleseriu, A. Barkan, M. Del Pilar Schneider, Y. Darhi, A. de Pierrefeu, A. Ribeiro-Oliveira, et al. Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States. Pituitary. 2022. https:\/\/doi.org\/10.1007\/s11102-021-01198-5","DOI":"10.1007\/s11102-021-01198-5"},{"issue":"9","key":"3447_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/ERC-16-0553","volume":"24","author":"M Terzolo","year":"2017","unstructured":"M. Terzolo, G. Reimondo, P. Berchialla, E. Ferrante, E. Malchiodi, L. De Marinis et al. Acromegaly is associated with increased cancer risk: a survey in Italy. Endocr. Relat. Cancer 24(9), 495\u2013504 (2017). https:\/\/doi.org\/10.1530\/ERC-16-0553","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"3447_CR12","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1210\/jcem.83.8.5007","volume":"83","author":"SM Orme","year":"1998","unstructured":"S.M. Orme, R.J. McNally, R.A. Cartwright, P.E. Belchetz, Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab. 83(8), 2730\u20132734 (1998). https:\/\/doi.org\/10.1210\/jcem.83.8.5007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3447_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-16-0117","volume":"175","author":"J Dal","year":"2016","unstructured":"J. Dal, U. Feldt-Rasmussen, M. Andersen, L.\u00d8. Kristensen, P. Laurberg, L. Pedersen et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur. J. Endocrinol. 175(3), 181\u2013190 (2016). https:\/\/doi.org\/10.1530\/EJE-16-0117","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"3447_CR14","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1210\/jc.2015-2372","volume":"100","author":"D Petroff","year":"2015","unstructured":"D. Petroff, A. T\u00f6njes, M. Grussendorf, M. Droste, C. Dimopoulou, G. Stalla et al. The incidence of cancer among acromegaly patients: results from the German Acromegaly Registry. J. Clin. Endocrinol. Metab. 100(10), 3894\u20133902 (2015). https:\/\/doi.org\/10.1210\/jc.2015-2372","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"3447_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/er.2018-00166","volume":"40","author":"CL Boguszewski","year":"2019","unstructured":"C.L. Boguszewski, M.C.D.S. Boguszewski, Growth hormone\u2019s links to cancer. Endocr. Rev. 40(2), 558\u2013574 (2019). https:\/\/doi.org\/10.1210\/er.2018-00166","journal-title":"Endocr. Rev."},{"issue":"6","key":"3447_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.20945\/2359-3997000000186","volume":"63","author":"V Chesnokova","year":"2019","unstructured":"V. Chesnokova, S. Melmed, Growth hormone in the tumor microenvironment. Arch. Endocrinol. Metab. 63(6), 568\u2013575 (2019). https:\/\/doi.org\/10.20945\/2359-3997000000186","journal-title":"Arch. Endocrinol. Metab."},{"issue":"1","key":"3447_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4158\/EP-2020-0398","volume":"27","author":"B Ucan","year":"2021","unstructured":"B. Ucan, M. Kizilgul, A.C. Karci, H. Duger, M. Erkam Sencar, N.N. Imga et al. The prevalence of cancer and its relation to disease activity in patients with acromegaly: two centers' experience. Endocr. Pr. 27(1), 51\u201355 (2021). https:\/\/doi.org\/10.4158\/EP-2020-0398","journal-title":"Endocr. Pr."},{"issue":"22","key":"3447_CR18","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.3748\/wjg.14.3484","volume":"14","author":"T Rokkas","year":"2008","unstructured":"T. Rokkas, D. Pistiolas, P. Sechopoulos, G. Margantinis, G. Koukoulis, Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J. Gastroenterol. 14(22), 3484\u20133489 (2008). https:\/\/doi.org\/10.3748\/wjg.14.3484","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"3447_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cen.14468","volume":"95","author":"M Thomas","year":"2021","unstructured":"M. Thomas, E. Berni, S. Jenkins-Jones, S. Wensley, C.D. Poole, C.J. Currie et al. Insulin-like growth factor-1, growth hormone and disease outcomes in acromegaly: a population study. Clin. Endocrinol. 95(1), 143\u2013152 (2021). https:\/\/doi.org\/10.1111\/cen.14468","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"3447_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11102-020-01090-8","volume":"24","author":"MF Battistone","year":"2021","unstructured":"M.F. Battistone, K. Miragaya, A. Rogozinski, M. Ag\u00fcero, A. Alfieri, M.C. Ballarino et al. Increased risk of preneoplastic colonic lesions and colorectal carcinoma in acromegaly: multicenter case-control study. Pituitary 24(1), 96\u2013103 (2021). https:\/\/doi.org\/10.1007\/s11102-020-01090-8","journal-title":"Pituitary"},{"issue":"3","key":"3447_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/BF03343997","volume":"25","author":"M Gasperi","year":"2002","unstructured":"M. Gasperi, E. Martino, L. Manetti, M. Arosio, S. Porretti, G. Faglia et al. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J. Endocrinol. Invest. 25(3), 240\u2013245 (2002). https:\/\/doi.org\/10.1007\/BF03343997","journal-title":"J. Endocrinol. Invest."},{"issue":"8","key":"3447_CR22","doi-asserted-by":"publisher","first-page":"e104174","DOI":"10.1371\/journal.pone.0104174","volume":"9","author":"JL Reverter","year":"2014","unstructured":"J.L. Reverter, C. Fajardo, E. Resmini, I. Salinas, M. Mora, M. Llatj\u00f3s et al. Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? PLoS ONE 9(8), e104174 (2014). https:\/\/doi.org\/10.1371\/journal.pone.0104174","journal-title":"PLoS ONE"},{"key":"3447_CR23","doi-asserted-by":"publisher","first-page":"610519","DOI":"10.3389\/fendo.2020.610519","volume":"11","author":"X Guo","year":"2020","unstructured":"X. Guo, K. Wang, S. Yu, L. Gao, Z. Wang, H. Zhu et al. Patient characteristics, diagnostic delays, treatment patterns, treatment outcomes, comorbidities, and treatment costs of acromegaly in China: a nationwide study. Front. Endocrinol. 11, 610519 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.610519","journal-title":"Front. Endocrinol."},{"issue":"1","key":"3447_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EJE-09-1080","volume":"163","author":"D Dworakowska","year":"2010","unstructured":"D. Dworakowska, M. Gueorguiev, P. Kelly, J.P. Monson, G.M. Besser, S.L. Chew et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur. J. Endocrinol. 163(1), 21\u201328 (2010). https:\/\/doi.org\/10.1530\/EJE-09-1080","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3447_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4158\/EP-2019-0254","volume":"26","author":"NB Lai","year":"2020","unstructured":"N.B. Lai, D. Garg, A.P. Heaney, M. Bergsneider, A.M. Leung, No benefit of dedicated thyroid nodule screening in patients with acromegaly. Endocr. Pr. 26(1), 16\u201321 (2020). https:\/\/doi.org\/10.4158\/EP-2019-0254","journal-title":"Endocr. Pr."},{"issue":"11","key":"3447_CR26","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"L. Katznelson, E.R. Laws, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933\u20133951 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 4","key":"3447_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/ep.17.s4.1","volume":"17","author":"L Katznelson","year":"2011","unstructured":"L. Katznelson, J.L.D. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20132011 update. Endocr. Pr. 17(Suppl 4), 1\u201344 (2011). https:\/\/doi.org\/10.4158\/ep.17.s4.1","journal-title":"Endocr. Pr."},{"issue":"9","key":"3447_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass et al. A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u2013561 (2018). https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"3447_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","volume":"2","author":"R Zheng","year":"2022","unstructured":"R. Zheng, S. Zhang, H. Zeng, S. Wang, K. Sun, R. Chen et al. Cancer incidence and mortality in China, 2016. J. Natl Cancer Cent. 2(1), 1\u20139 (2022). https:\/\/doi.org\/10.1016\/j.jncc.2022.02.002","journal-title":"J. Natl Cancer Cent."},{"issue":"1","key":"3447_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11102-016-0744-z","volume":"20","author":"A Tirosh","year":"2017","unstructured":"A. Tirosh, I. Shimon, Complications of acromegaly: thyroid and colon. Pituitary 20(1), 70\u201375 (2017). https:\/\/doi.org\/10.1007\/s11102-016-0744-z","journal-title":"Pituitary"},{"issue":"15","key":"3447_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.46234\/ccdcw2022.036","volume":"4","author":"X Fan","year":"2022","unstructured":"X. Fan, B. Zhang, Y. He, X. Zhou, Y. Zhang, L. Ma et al. Burden of disease due to cancer\u2014China, 2000-2019. China CDC Wkly 4(15), 306\u2013311 (2022). https:\/\/doi.org\/10.46234\/ccdcw2022.036","journal-title":"China CDC Wkly"},{"key":"3447_CR32","doi-asserted-by":"publisher","unstructured":"D. Esposito, O. Ragnarsson, G. Johannsson, D.S. Olsson, Incidence of benign and malignant tumors in patients with acromegaly is increased: a nationwide population-based study. J. Clin. Endocrinol. Metab. 2021. https:\/\/doi.org\/10.1210\/clinem\/dgab560","DOI":"10.1210\/clinem\/dgab560"},{"key":"3447_CR33","doi-asserted-by":"publisher","first-page":"101378","DOI":"10.1016\/j.ghir.2021.101378","volume":"56","author":"IY Spricido","year":"2021","unstructured":"I.Y. Spricido, C.M. Feckinghaus, R.H.M. Silva, C.O. Mesa Junior, C.L. Boguszewski, Prevalence of thyroid cancer in patients with acromegaly and non-growth hormone secreting pituitary adenomas: a prospective cross-sectional study. Growth Horm. IGF Res. 56, 101378 (2021). https:\/\/doi.org\/10.1016\/j.ghir.2021.101378","journal-title":"Growth Horm. IGF Res."},{"key":"3447_CR34","doi-asserted-by":"publisher","first-page":"6546832","DOI":"10.1155\/2018\/6546832","volume":"2018","author":"X Wu","year":"2018","unstructured":"X. Wu, L. Gao, X. Guo, Q. Wang, Z. Wang, W. Lian et al. GH, IGF-1, and age are important contributors to thyroid abnormalities in patients with acromegaly. Int. J. Endocrinol. 2018, 6546832 (2018). https:\/\/doi.org\/10.1155\/2018\/6546832","journal-title":"Int. J. Endocrinol."},{"issue":"1","key":"3447_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1507\/endocrj.k07e-010","volume":"55","author":"M Kurimoto","year":"2008","unstructured":"M. Kurimoto, I. Fukuda, N. Hizuka, K. Takano, The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J. 55(1), 67\u201371 (2008). https:\/\/doi.org\/10.1507\/endocrj.k07e-010","journal-title":"Endocr J."},{"issue":"6","key":"3447_CR36","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S2213-8587(20)30115-7","volume":"8","author":"M Li","year":"2020","unstructured":"M. Li, L. Dal Maso, S. Vaccarella, Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 8(6), 468\u2013470 (2020). https:\/\/doi.org\/10.1016\/S2213-8587(20)30115-7","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"3447_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S2213-8587(21)00083-8","volume":"9","author":"M Li","year":"2021","unstructured":"M. Li, R. Zheng, L. Dal Maso, S. Zhang, W. Wei, S. Vaccarella, Mapping overdiagnosis of thyroid cancer in China. Lancet Diabetes Endocrinol. 9(6), 330\u2013332 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00083-8","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3447_CR38","doi-asserted-by":"publisher","first-page":"924952","DOI":"10.3389\/fendo.2022.924952","volume":"13","author":"L Kasuki","year":"2022","unstructured":"L. Kasuki, B. Maia, M.R. Gadelha, Acromegaly and colorectal neoplasm: an update. Front. Endocrinol. 13, 924952 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.924952","journal-title":"Front. Endocrinol."},{"issue":"4","key":"3447_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.21457","volume":"68","author":"AMD Wolf","year":"2018","unstructured":"A.M.D. Wolf, E.T.H. Fontham, T.R. Church, C.R. Flowers, C.E. Guerra, S.J. LaMonte et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin. 68(4), 250\u2013281 (2018). https:\/\/doi.org\/10.3322\/caac.21457","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"3447_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40618-019-01138-y","volume":"43","author":"A Colao","year":"2020","unstructured":"A. Colao, L.F.S. Grasso, M. Di Cera, P. Thompson-Leduc, W.Y. Cheng, H.C. Cheung et al. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study. J. Endocrinol. Invest. 43(4), 529\u2013538 (2020). https:\/\/doi.org\/10.1007\/s40618-019-01138-y","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"3447_CR41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","volume":"106","author":"C Campana","year":"2021","unstructured":"C. Campana, F. Cocchiara, G. Corica, F. Nista, M. Arvigo, J. Amar\u00f9 et al. Discordant GH and IGF-1 results in treated acromegaly: impact of GH cutoffs and mean values assessment. J. Clin. Endocrinol. Metab. 106(3), 789\u2013801 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa859","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03447-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03447-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03447-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T07:08:37Z","timestamp":1696057717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03447-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03447-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"assertion":[{"value":"8 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all individual participants included in the study during their hospitalization. Verbal informed consent was obtained in the telephone interview.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was approved by the PUMCH ethics office (Ethical Approval Number: S-K1617). Written informed consent was obtained from patients to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}